My­ovant lands a fresh $200M loan as FDA mar­ket­ing de­ci­sion looms; Amarin goes it alone in Eu­rope

My­ovant is get­ting ready to roll out its com­mer­cial op­er­a­tions to back re­l­u­golix, now un­der FDA re­view for prostate can­cer.

The start­up has added a fresh $200 mil­lion in sup­port from Sum­it­o­mo Dainip­pon Phar­ma, which con­trols a ma­jor­i­ty of the stock $MY­OV. Sum­it­o­mo is hand­ing the cash over as a loan, bring­ing its to­tal to $600 mil­lion. My­ovant — which is gear­ing up for a show­down with Ab­b­Vie — has al­so filed an NDA to sell re­l­u­golix for uter­ine fi­broids and re­cent­ly post­ed pos­i­tive late-stage da­ta for en­dometrio­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER